ABSTRACT
BACKGROUND: Non-tuberculous mycobacteria (NTM) are present widely in the natural environment and can invade the human body through the respiratory tract, gastrointestinal tract, and skin. Immunocompromised patients are particularly prone to infection, which primarily affects multiple organs, including the lungs, lymph nodes, and skin. However, cases of NTM bloodstream infections are rare. Here, we report a rare case of Mycobacterium marseillense bloodstream infection with concurrent skin fungal infection in a patient after kidney transplantation. Related literature was reviewed to enhance the understanding of this rare condition. CASE PRESENTATION: A 58-year-old male with a history of long-term steroid and immunosuppressant use after kidney transplantation presented with limb swelling that worsened over the past two months. Physical examination revealed redness and swelling of the skin in all four limbs, with a non-healing wound on the lower left limb. Skin tissue analysis by metagenomic next-generation sequencing (mNGS) and fungal culture indicated infection with Trichophyton rubrum. Blood culture results suggested infection with Mycobacterium marseillense. After receiving anti-NTM treatment, the patient's symptoms significantly improved, and he is currently undergoing treatment. CONCLUSION: Mycobacterium marseillense is a NTM. Gram staining suffered from misdetection, and the acid-fast staining result was positive. This bacterium was identified by mass spectrometry and mNGS analyses. Antimicrobial susceptibility tests for NTM were performed using the broth microdilution method. The results of the susceptibility test showed that Mycobacterium marseillense was sensitive to clarithromycin, an intermediary between moxifloxacin and linezolid. Bacterial clearance requires a combination of drugs and an adequate course of treatment. NTM bloodstream infections are relatively rare, and early identification and proactive intervention are key to their successful management.
Subject(s)
Mycobacterium Infections, Nontuberculous , Humans , Male , Middle Aged , Mycobacterium Infections, Nontuberculous/microbiology , Mycobacterium Infections, Nontuberculous/drug therapy , Dermatomycoses/microbiology , Dermatomycoses/drug therapy , Kidney Transplantation/adverse effects , Immunocompromised Host , Anti-Bacterial Agents/therapeutic use , Nontuberculous Mycobacteria/isolation & purification , Nontuberculous Mycobacteria/drug effects , Bacteremia/microbiology , Bacteremia/drug therapy , Mycobacterium/isolation & purification , Mycobacterium/drug effects , Skin/microbiology , Skin/pathologyABSTRACT
BACKGROUND: Dermatophytosis is a common skin infection of cats and many other animals. A reliable diagnosis is crucial because of the zoonotic potential of dermatophytes. The routine mycological diagnostic procedures for dermatophytosis are widely known, but in the case of some isolates, identification based on phenotypic characteristics may be incorrect. Infections caused by Chrysosporium spp. are usually described in reptiles, but in other animals they are uncommon. CASE PRESENTATION: This study presents a description of a cat with dermatological lesions, that was mistakenly diagnosed with Trichophyton spp. dermatophytosis. Clinical material for mycological examination was collected from alopecic areas on the back of the neck, the ventral abdomen, and the hindlimbs. The initial identification based on phenotypic properties indicated Trichophyton spp. The result of the MALDI-ToF MS allowed the exclusion of the Trichophyton genus. Ultimately, the correct identification as Chrysosporium articulatum was obtained based on the sequencing of ribosomal genes. CONCLUSIONS: Interpretation of the results of the mycological examination of samples collected from animals' skin or hair shafts is always challenging. Thus, careful consideration of the primary cause of the clinical lesions observed on the skin is mandatory, and the culture results are worth supporting by molecular methods.
Subject(s)
Cat Diseases , Chrysosporium , Tinea , Trichophyton , Cats , Animals , Cat Diseases/microbiology , Cat Diseases/diagnosis , Tinea/veterinary , Tinea/diagnosis , Tinea/microbiology , Chrysosporium/isolation & purification , Chrysosporium/genetics , Trichophyton/isolation & purification , Diagnosis, Differential , Male , Dermatomycoses/veterinary , Dermatomycoses/diagnosis , Dermatomycoses/microbiologyABSTRACT
BACKGROUND: Cryptococcosis is an infectious disease caused by encapsulated heterobasidiomycete yeasts. As an opportunistic pathogen, cryptococcal inhalation infection is the most common. While Primary cutaneous cryptococcosis is extremely uncommon. CASE PRESENTATION: A 61-year-old woman with a history of rheumatoid arthritis on long-term prednisone developed a red plaque on her left thigh. Despite initial antibiotic treatment, the erythema worsened, leading to rupture and fever. Microbiological analysis of the lesion's secretion revealed Candida albicans, Pseudomonas aeruginosa, and methicillin-resistant Staphylococcus epidermidis. Skin biopsy showed thick-walled spores, and culture confirmed primary cutaneous infection with Cryptococcus neoformans. Histopathological stains were positive, and mass spectrometry identified serotype A of the pathogen. The patient was treated with oral fluconazole and topical nystatin, resulting in significant improvement and near-complete healing of the skin lesion within 2.5 months. CONCLUSIONS: Primary cutaneous cryptococcosis was a primary skin infection exclusively located on the skin. It has no typical clinical manifestation of cutaneous infection of Cryptococcus, and culture and histopathology remain the gold standard for diagnosing. The recommended medication for Primary cutaneous cryptococcosis is fluconazole. When patients at risk for opportunistic infections develop skin ulcers that are unresponsive to antibiotic, the possibility of primary cutaneous cryptococcosis needs to be considered.
Subject(s)
Antifungal Agents , Cryptococcosis , Cryptococcus neoformans , Fluconazole , Humans , Female , Middle Aged , Cryptococcus neoformans/isolation & purification , Cryptococcus neoformans/drug effects , Cryptococcosis/drug therapy , Cryptococcosis/microbiology , Cryptococcosis/diagnosis , Cryptococcosis/pathology , Antifungal Agents/therapeutic use , Fluconazole/therapeutic use , Dermatomycoses/drug therapy , Dermatomycoses/microbiology , Dermatomycoses/diagnosis , Dermatomycoses/pathology , Skin/pathology , Skin/microbiology , Treatment Outcome , Arthritis, Rheumatoid/drug therapy , Arthritis, Rheumatoid/complicationsABSTRACT
Cutaneous fungal infections are one of the most common skin conditions, hence, the burden of determining fungal elements upon microscopic examination with periodic acid-Schiff (PAS) and Gomori methenamine silver (GMS) stains, is very time consuming. Despite some morphological variability posing challenges to training artificial intelligence (AI)-based solutions, these structures are favored potential targets, enabling the recruitment of promising AI-based technologies. Herein, we present a novel AI solution for identifying skin fungal infections, potentially providing a decision support system for pathologists. Skin biopsies of patients diagnosed with a cutaneous fungal infection at the Sheba Medical Center, Israel between 2014 and 2023, were used. Samples were stained with PAS and GMS and digitized by the Philips IntelliSite scanner. DeePathology® STUDIO fungal elements were annotated and deemed as ground truth data after an overall revision by two specialist pathologists. Subsequently, they were used to create an AI-based solution, which has been further validated in other regions of interests. The study participants were divided into two cohorts. In the first cohort, the overall sensitivity of the algorithm was 0.8, specificity 0.97, F1 score 0.78; in the second, the overall sensitivity of the algorithm was 0.93, specificity 0.99, F1 score 0.95. The results obtained are encouraging as proof of concept for an AI-based fungi detection algorithm. DeePathology® STUDIO can be employed as a decision support system for pathologists when diagnosing a cutaneous fungal infection using PAS and GMS stains, thereby, saving time and money.
Subject(s)
Artificial Intelligence , Dermatomycoses , Humans , Dermatomycoses/diagnosis , Dermatomycoses/microbiology , Dermatomycoses/pathology , Decision Support Systems, Clinical , Female , BiopsyABSTRACT
BACKGROUND: Fungi clinically relevant to human skin comprise prevalent commensals and well-known pathogens. Only rarely human skin harbours fungi that evade identification. OBJECTIVE: To characterise an enigmatic specimen isolated from a skin lesion. METHODS: A comprehensive clinical and mycological workup including conventional methods for phenotypic characterisation and sequencing based on internal transcribed spacer (ITS) and large subunit (LSU) regions to infer a phylogenetic tree. RESULTS: Cultures on common solid media were macroscopically inconspicuous initially until mycelial tufts developed on the surface, notably on potato dextrose agar. Polymorphous chlamydospores were detected but no aleurospores and ascomata. At 26°C, the isolate grew on standard agars, plant materials and garden soil and utilised peptone, keratins, lipids, inulin, erythrocytes and cellulose. It also grew at 5°C and at 37°C. Nucleotide sequences of its ITS region showed 93% similarity to sequences of different Malbranchea species. The closest matches among LSU rRNA sequences were obtained with the genera Amauroascus, Arthroderma, Auxarthronopsis and Malbranchea (93%-95%). A combined phylogenetic analysis placed the fungus in a sister clade to Neogymnomycetaceae, classified as incertae sedis in Onygenales, on a large distance to either Diploospora rosea or 'Amauroascus' aureus. CONCLUSIONS: The genus Inopinatus gen. nov. (MB854685) with the species Inopinatus corneliae sp. nov. (MB854687) is introduced to accommodate our isolate (holotype: DSM 116806; isotypes: CBS 151104, IHEM 29063). Probably Inopinatus corneliae is a geophilic species that, although potentially harmful, was no relevant pathogen in our case. Its ecology, epidemiology and pathogenicity need to be further clarified.
Subject(s)
DNA, Fungal , DNA, Ribosomal Spacer , Onygenales , Phylogeny , Sequence Analysis, DNA , Skin , Humans , Skin/microbiology , Onygenales/genetics , Onygenales/classification , Onygenales/isolation & purification , DNA, Fungal/genetics , DNA, Ribosomal Spacer/genetics , Dermatomycoses/microbiology , Keratins/metabolism , DNA, Ribosomal/genetics , Male , Mycological Typing TechniquesABSTRACT
Trichophyton indotineae is a recently identified dermatophyte that frequently causes extensive and persistent dermatomycosis, particularly tinea corporis, tinea cruris, and tinea faciei. The infection is frequently encountered in countries of the Indian subcontinent and surrounding areas. In Europe, T. indotineae has mainly been detected in patients with an epidemiological link to the aforementioned regions. Unlike dermatomycoses caused by other dermatophyte species, infections caused by T. indotineae often exhibit treatment failure with commonly prescribed antifungal drugs. Reduced susceptibility to terbinafine is often observed in T. indotineae. In addition, reduced susceptibility to itraconazole has also been reported. Due to the extensive and persistent nature of the infection, as well as the reduced susceptibility to antifungal drugs, international experts recommend aggressive treatment of T. indotineae using a combination of oral and topical antifungals. Susceptibility testing may be warranted to guide treatment decisions. Early recognition of T. indotineae infections is crucial to prevent prolonged recurrences.
Subject(s)
Antifungal Agents , Tinea , Humans , Antifungal Agents/therapeutic use , Tinea/drug therapy , Tinea/diagnosis , Trichophyton/isolation & purification , Trichophyton/drug effects , Dermatomycoses/drug therapy , Dermatomycoses/diagnosisABSTRACT
BACKGROUND: Fungal skin diseases are common skin diseases with a heterogeneous distribution worldwide. OBJECTIVES: This study aimed to analyse the spatiotemporal trends in the burden of fungal skin diseases at global, regional, and national levels from 1990 to 2021. METHODS: Based on the data obtained from the Global Burden of Disease Study (GBD) 2021, we described the incident cases, prevalent cases, number of disability-adjusted life years (DALYs), and corresponding age-standardised rates (ASRs) for fungal skin diseases in 1990 and 2021 by sex, age, socio-demographic index (SDI), 21 GBD regions, and 204 countries and territories. We used Joinpoint regression analysis to assess the temporal trends in burden of fungal skin diseases during 1990 to 2021. Spearman's rank test was used to analyse the relationship between disease burden and potential factors. RESULTS: From 1990 to 2021, the incident cases, prevalent cases, and DALYs for fungal skin diseases worldwide increased by 67.93%, 67.73%, and 66.77%, respectively. Globally, the age-standardised incidence rate (ASIR), age-standardised prevalence rate (ASPR), and age-standardised DALYs rate (ASDR) for fungal skin diseases in 2021 were 21668.40 per 100,000 population (95% UI: 19601.19-23729.17), 7789.55 per 100,000 population (95% UI: 7059.28-8583.54), and 43.39 per 100,000 population (95% UI: 17.79-89.10), respectively. Between 1990 and 2021, the ASIR, ASPR, and ASDR for fungal skin diseases have modestly increased, with AAPC of 11.71% (95% confidence interval [CI]: 11.03%-12.39%), 19.24% (95% CI: 18.12%-20.36%), and 20.25% (95% CI: 19.33%-21.18%), respectively. Males experienced a higher burden of fungal skin diseases than females. The incident cases, prevalent cases, and DALYs for fungal skin diseases were highest at the age of 5-9, while the ASRs were highest among the elderly. At national level, the highest ASRs were observed in Nigeria, Ethiopia, and Mali. Overall, SDI was negatively correlated with the ASRs, whereas Global Land-Ocean Temperature Index (GLOTI) was remarkably positively correlated with the burden of fungal skin diseases. CONCLUSIONS: Between 1990 and 2021, the global burden of fungal skin diseases has increased, causing a high disease burden worldwide, particularly in underdeveloped regions and among vulnerable population such as children and the elderly. With global warming and aging of the population, the burden of fungal skin diseases may continue to increase in the future. Targeted and specific measures should be taken to address these disparities and the ongoing burden of fungal skin diseases.
Subject(s)
Dermatomycoses , Global Burden of Disease , Global Health , Humans , Male , Female , Adult , Dermatomycoses/epidemiology , Middle Aged , Prevalence , Incidence , Young Adult , Global Health/statistics & numerical data , Adolescent , Aged , Disability-Adjusted Life Years , Child, Preschool , Child , Infant , Infant, Newborn , Aged, 80 and over , Cost of IllnessABSTRACT
BACKGROUND: dermatophytoses are a current fungal infection, caused by keratinophilic fungi (dermatophytes) able to invade the nails, hair and skin of humans and animals. AIM: the aim of this study was to establish the epidemiological and mycological profile of dermatophytes isolated in the parasitology-mycology laboratory of the Mohammed VI University Hospital in Oujda. METHODS: this is a 48-month retrospective study from January 2019 to December 2022.The study includes samples taken or sent to our parasitology-mycology laboratory for mycological study. A direct examination and culture were performed on each biological specimen. Species identification was based on macroscopic and microscopic colony criteria. RESULTS: in the present report we reviewed 950 mycological samples. Dermatophytes were isolated in 505 (53.15%) cases. The most common infections were tinea unguium (n=353; 69.90%), followed by tinea corporis (n=123; 5.74%) and tinea capitis (n=29; 5.98%). Trichophyton rubrum was the most frequently incriminated species. CONCLUSION: dermatophytes are the most frequent mycoses in humans. They are generally benign and often develop in a chronic and frequently recurrent pattern. Mycological examination is essential. It confirms the fungal origin and isolates the species responsible, in order to identify the source of contamination and implement an appropriate treatment.
Subject(s)
Arthrodermataceae , Hospitals, University , Humans , Retrospective Studies , Arthrodermataceae/isolation & purification , Female , Male , Adult , Middle Aged , Child , Adolescent , Young Adult , Aged , Child, Preschool , Tinea/epidemiology , Tinea/microbiology , Tinea/diagnosis , Dermatomycoses/epidemiology , Dermatomycoses/microbiology , Dermatomycoses/diagnosis , Morocco/epidemiology , Infant , Mycology/methods , Aged, 80 and overABSTRACT
A 3-year-old castrated male golden retriever was presented for evaluation of 2 cutaneous masses along the abdominal midline and a 6-month history of progressive lethargy and inappetence. Two years earlier, the dog underwent a gastrotomy to retrieve a foreign object and recovered uneventfully. Fluid aspirated from the lesions was culture-negative for aerobic and anaerobic bacterial growth. Abdominal ultrasound demonstrated a large intra-abdominal mass with apparent communication with the cutaneous lesion, along with gossypiboma from the previous laparotomy. Neoplasia or a sterile abscess were suspected. Exploratory laparotomy was performed and revealed that the intra-abdominal mass was adhered to the abdominal midline and the greater curvature of the stomach. The masses and affected portions of the body wall and stomach were resected and histopathology was consistent with phaeohyphomycosis. Antifungal therapy with voriconazole (6.3 mg/kg, PO, q12h) was initiated. At 1 mo after surgery, all clinical signs had resolved. At 4 and 7 mo after surgery, the dog continued to thrive despite 2 small masses, seen on abdominal ultrasound imaging on the intra-abdominal midline, suggestive of reoccurrence. Continued voriconazole therapy was administered in lieu of further surgical excision. One year after surgery, the masses were no longer present on ultrasonographic evaluation. Phaeohyphomycosis is a rare, opportunistic fungal infection that typically affects the dermis and subcutis of immunocompromised dogs. This is the first report of phaeohyphomycosis in an immunocompetent dog and involving the dermis, subcutis, and abdominal viscera. Key clinical message: This case adds to the very limited literature on phaeohyphomycosis in dogs and illustrates that surgery could be a risk factor for infection, even in dogs with no known underlying disease or immunodeficiency.
Phéohyphomycose cutanée et viscérale chez un golden retriever immunocompétentUn golden retriever mâle castré de 3 ans a été présenté pour évaluation de 2 masses cutanées le long de la ligne médiane abdominale et d'un historique de léthargie et d'inappétence progressive depuis 6 mois. Deux ans plus tôt, le chien avait subi une gastrotomie pour récupérer un objet étranger et s'était rétabli sans incident. Le liquide aspiré des lésions était négatif en culture pour la croissance bactérienne aérobie et anaérobie. L'échographie abdominale a mis en évidence une masse intra-abdominale importante avec une communication apparente avec la lésion cutanée, ainsi qu'un gossyibome issu de la laparotomie précédente. Un néoplasme ou un abcès stérile ont été suspectés. Une laparotomie exploratoire a été réalisée et a révélé que la masse intra-abdominale adhérait à la ligne médiane abdominale et à la grande courbure de l'estomac. La masse et les parties affectées de la paroi corporelle et de l'estomac ont été réséquées et l'histopathologie était compatible avec une phaeohyphomycose. Un traitement antifongique par voriconazole (6,3 mg/kg, PO, toutes les 12 heures) a été instauré. Un mois après l'intervention chirurgicale, tous les signes cliniques avaient disparu. À 4 et 7 mois après l'intervention chirurgicale, le chien a continué à bien allé malgré 2 petites masses, observées à l'échographie abdominale sur la ligne médiane intra-abdominale, évocatrices d'une réapparition. La poursuite du traitement par le voriconazole a été administrée au lieu d'une nouvelle excision chirurgicale. Un an après l'intervention chirurgicale, les masses n'étaient plus présentes à l'évaluation échographique. La phaeohyphomycose est une infection fongique rare et opportuniste qui affecte généralement le derme et le sous-cutané des chiens immunodéprimés. Il s'agit du premier rapport de phaeohyphomycose chez un chien immunocompétent et impliquant le derme, le tissu sous-cutané et les viscères abdominaux.Message clinique clé :Ce cas s'ajoute à la littérature très limitée sur la phaeohyphomycose chez le chien et illustre que la chirurgie pourrait être un facteur de risque d'infection, même chez les chiens sans maladie sous-jacente ou immunodéficience connue.(Traduit par Dr Serge Messier).
Subject(s)
Antifungal Agents , Dog Diseases , Phaeohyphomycosis , Animals , Dogs , Male , Dog Diseases/microbiology , Dog Diseases/surgery , Dog Diseases/drug therapy , Phaeohyphomycosis/veterinary , Phaeohyphomycosis/drug therapy , Phaeohyphomycosis/diagnosis , Antifungal Agents/therapeutic use , Voriconazole/therapeutic use , Immunocompetence , Dermatomycoses/veterinary , Dermatomycoses/diagnosisABSTRACT
Primary cutaneous mucormycosis is caused by environmental fungi and may complicate leg ulcers or traumatic wounds even in immunocompetent individuals. This case report highlights recurrent lower limb ulcers and cellulitis in a patient with type two diabetes mellitus, which was unresponsive to conventional antibiotic treatment. Histopathology revealed the diagnosis of cutaneous mucormycosis, and fungal cultures identified Rhizopus variabilis as the causative organism. Initial courses of oral azole antifungals yielded only partial response and he eventually required more aggressive treatment with i.v. amphotericin B and oral posaconazole. Good treatment outcomes for this condition require a high index of clinical suspicion, early histopathological and microbiological diagnosis, targeted systemic antifungal therapy, and surgical debridement if necessary.
Subject(s)
Antifungal Agents , Cellulitis , Dermatomycoses , Diabetes Mellitus, Type 2 , Leg Ulcer , Mucormycosis , Humans , Mucormycosis/diagnosis , Mucormycosis/complications , Cellulitis/microbiology , Cellulitis/drug therapy , Male , Diabetes Mellitus, Type 2/complications , Antifungal Agents/therapeutic use , Leg Ulcer/microbiology , Dermatomycoses/diagnosis , Dermatomycoses/drug therapy , Dermatomycoses/pathology , Rhizomucor/isolation & purification , Amphotericin B/therapeutic use , Recurrence , Middle Aged , Triazoles/therapeutic use , Rhizopus/isolation & purificationABSTRACT
The present study analyses the clinical characteristics of patients diagnosed with cutaneous fusarium through a systematic review of cases reported in literature. A total of 39 cases were included, of which 53% were men, 30% were women, and in 17% the sex was not specified. The age ranged from 5 to 85 years. Most cases were reported in Brazil, followed by Japan and United States of America. The most common agent was Fusarium solani, in 37.5% of the patients. Most of the affected individuals had acute myeloid leukaemia and some of the predisposing factors, which included induction chemotherapy, febrile neutropenia, and bone marrow transplantation. The clinical topography of the lesions was located in 27.5% and disseminated in 72.5%, with the most observed clinical feature outstanding the presence of papules and nodules with central necrosis in 47% of the cases. Longer survival was demonstrated in those treated with more than three antifungals. It is concluded that cutaneous fusarium is a complex and challenging clinical entity, infection in patients with leukaemias underscores the need for thorough care to decrease morbidity and mortality.
Subject(s)
Antifungal Agents , Fusariosis , Fusarium , Humans , Fusariosis/drug therapy , Fusariosis/microbiology , Fusarium/isolation & purification , Aged , Adult , Antifungal Agents/therapeutic use , Middle Aged , Female , Male , Aged, 80 and over , Young Adult , Adolescent , Brazil/epidemiology , Child , Japan/epidemiology , Child, Preschool , Leukemia, Myeloid, Acute/complications , United States/epidemiology , Leukemia/complications , Leukemia/microbiology , Dermatomycoses/microbiology , Dermatomycoses/epidemiology , Dermatomycoses/drug therapy , Dermatomycoses/pathologyABSTRACT
Background: Dermatophytosis, commonly known as tinea, poses a significant public health concern worldwide, especially in environments with poor hygiene and overcrowding, such as prisons. Despite its prevalence and impact on quality of life, there is a lack of research on the knowledge and hygiene practices regarding dermatophytosis among prisoners, particularly in Nepal. Objective: The study aimed to assess prisoners' knowledge, hygiene practice and infection status regarding dermatophytosis in Central Prison, Nepal. Methods: A descriptive cross-sectional study with a sample size of 184 respondents was designed to collect data using a validated pre-tested questionnaire from September 2023 to January 2024. The collected data was then analyzed using IBM SPSS version 21. Knowledge and hygiene practices were measured on an eight and 11-point scale and rated as poor (≤4) and sound (>4), bad (≤6), and good (>6), respectively. Summary data were presented by descriptive, while Chi-square and logistic regression were used for inferential statistics at p < 0.05. Results: The findings revealed moderate knowledge among prisoners regarding dermatophytosis, with significant gaps in understanding its spread and prevention. While most prisoners recognized the importance of treatment, there were misconceptions about the inevitability of contracting dermatophytosis and the role of personal hygiene. Conclusion: Despite good knowledge levels, adherence to recommended hygiene practices was suboptimal, highlighting the need for targeted interventions. The study underscores the importance of addressing knowledge gaps, changing attitudes, and promoting hygienic practices to mitigate the burden of dermatophytosis among prisoners.
Subject(s)
Health Knowledge, Attitudes, Practice , Prisoners , Humans , Nepal/epidemiology , Cross-Sectional Studies , Male , Prisoners/statistics & numerical data , Adult , Surveys and Questionnaires , Female , Middle Aged , Hygiene , Dermatomycoses/epidemiology , Tinea/epidemiology , Young AdultABSTRACT
BACKGROUND: Current treatment options for Malassezia folliculitis (MF) are limited. Recent research has demonstrated the inhibitory effect of cold atmospheric plasma (CAP) on the growth of Malassezia pachydermatis in vitro, suggesting CAP as a potential therapeutic approach for managing MF. OBJECTIVES: The objective of our study is to assess the in vitro antifungal susceptibility of Malassezia yeasts to CAP. Additionally, we aim to evaluate the efficacy and tolerability of CAP in treating patients with MF. METHODS: We initially studied the antifungal effect of CAP on planktonic and biofilm forms of Malassezia yeasts, using well-established techniques such as zone of inhibition, transmission electron microscopy, colony count assay and 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide salt assay. Subsequently, a randomized (1:1 ratio), active comparator-controlled, observer-blind study was conducted comparing daily CAP therapy versus itraconazole 200 mg/day for 2 weeks in 50 patients with MF. Efficacy outcomes were measured by success rate, negative microscopy rate and changes in Dermatology Life Quality Index (DLQI) and Global Aesthetic Improvement Scale (GAIS) scores. Safety was assessed by monitoring adverse events (AEs) and local tolerability. RESULTS: In laboratory investigations, CAP time-dependently inhibited the growth of Malassezia yeasts in both planktonic and biofilm forms. Forty-nine patients completed the clinical study. At week 2, success was achieved by 40.0% of subjects in the CAP group versus 58.3% in the itraconazole group (p = 0.199). The negative direct microscopy rates of follicular samples were 56.0% in the CAP group versus 66.7% in the itraconazole group (p = 0.444). No significant differences were found in the proportion of subjects achieving DLQI scores of 0/1 (p = 0.456) or in the GAIS responder rates (p = 0.588) between the two groups. Three patients in the CAP group and one patient in the itraconazole group reported mild AEs. CONCLUSION: CAP demonstrated significant antifungal activity against Malassezia yeasts in vitro and exhibited comparable efficacy to itraconazole in treating MF patients. Without the associated adverse effects of oral antifungal drugs, CAP can be considered a promising and safe treatment modality for MF.
Subject(s)
Antifungal Agents , Dermatomycoses , Folliculitis , Malassezia , Plasma Gases , Malassezia/drug effects , Humans , Folliculitis/drug therapy , Folliculitis/microbiology , Plasma Gases/pharmacology , Plasma Gases/therapeutic use , Antifungal Agents/pharmacology , Antifungal Agents/therapeutic use , Adult , Female , Male , Middle Aged , Dermatomycoses/drug therapy , Dermatomycoses/microbiology , Itraconazole/therapeutic use , Itraconazole/pharmacology , Young Adult , Treatment Outcome , Biofilms/drug effectsABSTRACT
BACKGROUND: Malassezia yeasts are almost universally present on human skin worldwide. While they can cause diseases such as pityriasis versicolor, their implication in skin homeostasis and pathophysiology of other dermatoses is still unclear. Their analysis using native microscopy of skin tape strips is operator dependent and requires skill, training and significant amounts of hands-on time. OBJECTIVES AND METHODS: To standardise and improve the speed and quality of diagnosis of Malassezia in skin tape strip samples, we sought to create an artificial intelligence-based algorithm for this image classification task. Three algorithms, each using different internal architectures, were trained and validated on a manually annotated dataset of 1113 images from 22 samples. RESULTS: The Vision Transformer-based algorithm performed the best with a validation accuracy of 94%, sensitivity of 94.0% and specificity of 93.5%. Visualisations providing insight into the reasoning of the algorithm were presented and discussed. CONCLUSION: Our image classifier achieved very good performance in the diagnosis of the presence of Malassezia yeasts in tape strip samples of human skin and can therefore improve the speed and quality of, and access to this diagnostic test. By expanding data sources and explainability, the algorithm could also provide teaching points for more novice operators in future.
Subject(s)
Algorithms , Artificial Intelligence , Dermatomycoses , Malassezia , Skin , Malassezia/isolation & purification , Malassezia/classification , Malassezia/genetics , Humans , Skin/microbiology , Dermatomycoses/diagnosis , Dermatomycoses/microbiology , Sensitivity and Specificity , Image Processing, Computer-Assisted/methods , Microscopy/methodsABSTRACT
BACKGROUND: Fungal skin diseases are the most common and widespread fungal infections, exerting a significant impact on patients' socio-psychological health and the quality of life. OBJECTIVES: To assess and compare the global burden of fungal skin diseases in 2019 and over the past 30 years. METHODS: Data were retrieved from the Global Burden of Disease Study 2019. Incidence and years lived with disability (YLDs) were used to assess the burden of fungal skin diseases. A total of 204 countries and territories were hierarchically organised into 21 regions and seven super-regions. Data were presented as absolute numbers and rates per 100,000 population, stratified by sex, age, year and location. RESULTS: In 2019, the global incidence rate and YLD rate of fungal skin diseases were 21,277 (95% UI 19 298-23,399) and 42 (95% UI 17-88) per 100,000 population, respectively. Sub-Saharan Africa bore the heaviest disease burden, especially children aged 5-9 years had a significantly higher incidence rate, YLD rate and YLDs to incidence ratio compared to other regions. Moreover, more than half of the incident cases among the elderly came from high-income regions and Southeast Asia, East Asia, and Oceania. Over the past 30 years, the number of incident cases and YLDs of fungal skin diseases has been continuously increasing worldwide, but the incidence rates and YLD rates have not shown significant changes. CONCLUSIONS: The global burden of fungal skin diseases has been continuously rising. Children in Sub-Saharan Africa are experiencing higher disease incidence and severity compared to other regions.
Subject(s)
Dermatomycoses , Global Burden of Disease , Global Health , Humans , Child , Child, Preschool , Adolescent , Male , Adult , Female , Incidence , Dermatomycoses/epidemiology , Dermatomycoses/microbiology , Middle Aged , Young Adult , Aged , Infant , Global Health/statistics & numerical data , Infant, Newborn , Cost of Illness , Aged, 80 and over , Quality of Life , Africa South of the Sahara/epidemiologyABSTRACT
BACKGROUND: Fusarium and allied genera (fusarioid) species are common colonizers of roots and aerial plant parts, or act as phytopathogens in forestry and horticultural or grain crops. However, they can also cause a wide range of infections in humans, including onychomycosis, cutaneous and invasive infections. Fusarioid keratitis is characterized by an infection of the cornea with a suppurative and ulcerative appearance, which may cause damage to vision and permanent blindness. The aim of the present study was to investigate the prevalence of fusarioid species, biofilm formation and antifungal susceptibility profiling of clinical isolates recovered from patients with keratitis and dermatomycoses. METHODOLOGY/PRINCIPAL FINDINGS: The study was performed between March, 2012-December, 2022. Demographic, clinical and epidemiological data of patients were also collected. In the present study, most of the patients with keratitis were male (74%), had a median age of 42 years old, worked with plant material or debris and 26% of them reported eye trauma. Regarding dermatomycosis, most of patients were female and exhibited toenail lesions. Forty-seven isolates belonged to the genus Neocosmospora (78.33%), nine to the Fusarium fujikuroi (15%) and four to the Fusarium oxysporum (6.66%) species complexes. Several strains were moderate biofilm producers, specifically among Fusarium annulatum. Most strains showed increased MICs to amphotericin B and ketoconazole and low MICs to itraconazole. MICs ranged from 0.25 to 16 µg/mL for amphotericin B, 0.0625 to >16 µg/mL for ketoconazole and 0.125 to 8 for itraconazole. CONCLUSIONS/SIGNIFICANCE: It is possible to conclude that fusarioid keratitis in Northeastern Brazil is an important and neglected disease, given the high number of cases, increased need for keratoplasty and poor outcome of the disease.
Subject(s)
Antifungal Agents , Fusarium , Keratitis , Microbial Sensitivity Tests , Humans , Female , Male , Adult , Brazil/epidemiology , Keratitis/microbiology , Keratitis/epidemiology , Prospective Studies , Middle Aged , Antifungal Agents/pharmacology , Fusarium/drug effects , Fusarium/isolation & purification , Fusarium/classification , Fusariosis/microbiology , Fusariosis/epidemiology , Fusariosis/drug therapy , Young Adult , Dermatomycoses/epidemiology , Dermatomycoses/microbiology , Dermatomycoses/drug therapy , Aged , Biofilms/drug effects , Biofilms/growth & development , Prevalence , Adolescent , Eye Infections, Fungal/microbiology , Eye Infections, Fungal/epidemiology , Eye Infections, Fungal/drug therapyABSTRACT
INTRODUCTION: Terbinafine is considered the gold standard for treating skin fungal infections and onychomycosis. However, recent reports suggest that dermatophytes are developing resistance to terbinafine and the other traditional antifungal agents, itraconazole and fluconazole. When there is resistance to terbinafine, itraconazole or fluconazole, or when these agents cannot used, for example, due to potential drug interactions with the patient's current medications, clinicians may need to consider off-label use of new generation azoles, such as voriconazole, posaconazole, fosravuconazole, or oteseconazole. It is essential to emphasize that we do not advocate the use of newer generation azoles unless traditional agents such as terbinafine, itraconazole, or fluconazole have been thoroughly evaluated as first-line therapies. AREAS COVERED: This article reviews the clinical evidence, safety, dosage regimens, pharmacokinetics, and management algorithm of new-generation azole antifungals. EXPERT OPINION: Antifungal stewardship should be the top priority when prescribing new-generation azoles. First-line antifungal therapy is terbinafine and itraconazole. Fluconazole is a consideration but is generally less effective and its use may be off-label in many countries. For difficult-to-treat skin fungal infections and onychomycosis, that have failed terbinafine, itraconazole and fluconazole, we propose consideration of off-label voriconazole or posaconazole.